Derek M Yellon

List of Publications by Year
in descending order

280 papers	34,870 citations	2963 93 h-index	3563 181 g-index
292 all docs	292 docs citations	292 times ranked	26689 citing authors

#	Article	IF	Citations
1	Myocardial Reperfusion Injury. New England Journal of Medicine, 2007, 357, 1121-1135.	13.9	3,156
2	Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clinical Investigation, 2013, 123, 92-100.	3.9	1,687
3	Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology. Physiological Reviews, 2003, 83, 1113-1151.	13.1	925
4	New directions for protecting the heart against ischaemiaâ€"reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research, 2004, 61, 448-460.	1.8	873
5	Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury. Circulation, 2010, 121, 2012-2022.	1.6	845
6	Anthracycline Chemotherapy and Cardiotoxicity. Cardiovascular Drugs and Therapy, 2017, 31, 63-75.	1.3	654
7	Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. New England Journal of Medicine, 2015, 373, 1408-1417.	13.9	603
8	Postconditioning: A Form of â€œModified Reperfusionâ€•Protects the Myocardium by Activating the Phosphatidylinositol 3-Kinase-Akt Pathway. Circulation Research, 2004, 95, 230-232.	2.0	602
9	Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet, The, 2007, 370, 575-579.	6.3	598
10	Cardiovascular remodelling in coronary artery disease and heart failure. Lancet, The, 2014, 383, 1933-1943.	6.3	589
11	Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury. Diabetes, 2005, 54, 146-151.	0.3	551
12	Remote Ischemic Conditioning. Journal of the American College of Cardiology, 2015, 65, 177-195.	1.2	507
13	Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling. Circulation Research, 2001, 89, 1191-1198.	2.0	493
14	Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovascular Research, 2002, 55, 534-543.	1.8	487
15	Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury. Journal of the American College of Cardiology, 2019, 73, 89-99.	1.2	484
16	Postconditioning and protection from reperfusion injury: where do we stand? * Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2010, 87, 406-423.	1.8	447
17	Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovascular Research, 2008, 79, 377-386.	1.8	440
18	Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Failure Reviews, 2007, 12, 217-234.	1.7	436

#	Article	IF	Citations
19	Plasma Exosomes Protect the Myocardium From Ischemia-Reperfusion Injury. Journal of the American College of Cardiology, 2015, 65, 1525-1536.	1.2	436
20	Survival kinases in ischemic preconditioning and postconditioning. Cardiovascular Research, 2006, 70, 240-253.	1.8	425
21	Ischaemic conditioning and reperfusion injury. Nature Reviews Cardiology, 2016, 13, 193-209.	6.1	419
22	Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H971-H976.	1.5	416
23	The Reperfusion Injury Salvage Kinase Pathway: A Common Target for Both Ischemic Preconditioning and Postconditioning. Trends in Cardiovascular Medicine, 2005, 15, 69-75.	2.3	395
24	Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology, 2011, 50, 940-950.	0.9	376
25	Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemiaâ€“reperfusion injury. Cardiovascular Research, 2003, 60, 617-625.	1.8	350
26	Transient Mitochondrial Permeability Transition Pore Opening Mediates Preconditioning-Induced Protection. Circulation, 2004, 109, 1714-1717.	1.6	319
27	Myocardial reperfusion injury: looking beyond primary PCI. European Heart Journal, 2013, 34, 1714-1722.	1.0	318
28	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Research in Cardiology, 2018, 113, 39.	2.5	311
29	The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology, 2003, 35, 339-341.	0.9	301
30	Necrostatin: A Potentially Novel Cardioprotective Agent?. Cardiovascular Drugs and Therapy, 2007, 21, 227-233.	1.3	292
31	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 564-585.	1.8	278
32	Microvesicles and exosomes: new players in metabolic and cardiovascular disease. Journal of Endocrinology, 2016, 228, R57-R71.	1.2	270
33	Ischaemic conditioning and targeting reperfusion injury: a 30Âyear voyage of discovery. Basic Research in Cardiology, 2016, 111, 70.	2.5	257
34	Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or sizeâ€exclusion chromatography: yield, purity and functional potential. Journal of Extracellular Vesicles, 2019, 8, 1560809.	5.5	254
35	Preconditioning and postconditioning: United at reperfusion. , 2007, 116, 173-191.		246
36	Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovascular Research, 2007, 75, 530-535.	1.8	232

#	Article	IF	Citations
37	The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Research in Cardiology, 2009, 104, 189-202.	2.5	230
38	Preconditioning the Diabetic Heart: The Importance of Akt Phosphorylation. Diabetes, 2005, 54, 2360-2364.	0.3	228
39	Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway. Journal of the American College of Cardiology, 2003, 41, 508-515.	1.2	226
40	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet, The, 2019, 394, 1415-1424.	6.3	223
41	Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. European Heart Journal, 2017, 38, ehw145.	1.0	220
42	Urocortin Protects against Ischemic and Reperfusion Injury via a MAPK-dependent Pathway. Journal of Biological Chemistry, 2000, 275, 8508-8514.	1.6	216
43	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2013, 98, 7-27.	1.8	209
44	Preconditioning protects by inhibiting the mitochondrial permeability transition. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H841-H849.	1.5	205
45	The therapeutic potential of ischemic conditioning: an update. Nature Reviews Cardiology, 2011, 8, 619-629.	6.1	205
46	New Horizons in Cardioprotection. Circulation, 2011, 124, 1172-1179.	1.6	200
47	Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 178-188.	1.1	199
48	The neural and humoral pathways in remote limb ischemic preconditioning. Basic Research in Cardiology, 2010, 105, 651-655.	2.5	197
49	Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury. Basic Research in Cardiology, 2007, 102, 518-528.	2.5	187
50	Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Research in Cardiology, 2008, 103, 274-284.	2.5	185
51	Reducing myocardial infarct size: challenges and future opportunities. Heart, 2016, 102, 341-348.	1.2	185
52	Mitochondrial KATP channels: role in cardioprotection. Cardiovascular Research, 2002, 55, 429-437.	1.8	178
53	Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. International Journal of Biochemistry and Cell Biology, 2006, 38, 414-419.	1.2	167
54	Reperfusion Injury Salvage Kinase and Survivor Activating Factor Enhancement Prosurvival Signaling Pathways in Ischemic Postconditioning: Two Sides of the Same Coin. Antioxidants and Redox Signaling, 2011, 14, 893-907.	2.5	166

#	Article	IF	Citations
55	Statins and cardioprotection â€" More than just lipid lowering?. , 2009, 122, 30-43.		164
56	Exosomes. Circulation Research, 2014, 114, 325-332.	2.0	164
57	PI3 Kinase and not p42/p44 Appears to be Implicated in the Protection Conferred by Ischemic Preconditioning. Journal of Molecular and Cellular Cardiology, 2002, 34, 661-668.	0.9	161
58	Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart, 2015, 101, 185-192.	1.2	160
59	Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. European Heart Journal, 2011, 32, 23-31.	1.0	157
60	The RISK pathway and beyond. Basic Research in Cardiology, 2018, 113, 2.	2.5	156
61	Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. Journal of Molecular and Cellular Cardiology, 2003, 35, 185-193.	0.9	155
62	Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovascular Research, 2004, 63, 305-312.	1.8	155
63	Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1630-H1636.	1.5	154
64	Confounding factors in vesicle uptake studies using fluorescent lipophilic membrane dyes. Journal of Extracellular Vesicles, 2017, 6, 1388731.	5.5	152
65	Insulin Administered at Reoxygenation Exerts a Cardioprotective Effect in Myocytes by a Possible Anti-Apoptotic Mechanism. Journal of Molecular and Cellular Cardiology, 2000, 32, 757-764.	0.9	150
66	ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovascular Research, 2014, 104, 399-411.	1.8	143
67	Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1481-H1488.	1.5	142
68	Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment. Journal of the American College of Cardiology, 2005, 45, 1287-1291.	1.2	136
69	Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H237-H242.	1.5	135
70	The Second Window of Preconditioning (SWOP) Where Are We Now?. Cardiovascular Drugs and Therapy, 2010, 24, 235-254.	1.3	133
71	Adenosine A ₁ Receptor Induced Delayed Preconditioning in Rabbits. Circulation Research, 2000, 86, 989-997.	2.0	129
72	Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide. Circulation, 2001, 103, 3111-3116.	1.6	128

#	Article	IF	Citations
73	Targeting Myocardial Reperfusion Injury â€" The Search Continues. New England Journal of Medicine, 2015, 373, 1073-1075.	13.9	127
74	The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine, 2008, 12, 1395-1403.	1.6	125
75	Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. Journal of the American College of Cardiology, 2000, 36, 2296-2302.	1.2	124
76	Cardioprotection during cardiac surgery. Cardiovascular Research, 2012, 94, 253-265.	1.8	123
77	Postconditioning. Circulation, 2005, 112, 2085-2088.	1.6	121
78	Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segmentâ€"Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	120
79	Remote ischaemic preconditioning involves signalling through the SDF-1Î±/CXCR4 signalling axis. Basic Research in Cardiology, 2013, 108, 377.	2.5	119
80	Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1542-H1547.	1.5	112
81	Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2123-H2134.	1.5	112
82	Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway. Cardiovascular Drugs and Therapy, 2007, 21, 253-256.	1.3	111
83	Glycogen Synthase Kinase-3 Inactivation Is Not Required for Ischemic Preconditioning or Postconditioning in the Mouse. Circulation Research, 2008, 103, 307-314.	2.0	111
84	Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model. Cardiovascular Drugs and Therapy, 2005, 19, 9-11.	1.3	110
85	Heat shock protein 27 protects the heart against myocardial infarction. Basic Research in Cardiology, 2004, 99, 392-394.	2.5	107
86	Cardiac preconditioning for ischaemia: lost in translation. DMM Disease Models and Mechanisms, 2010, 3, 35-38.	1.2	105
87	Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Research in Cardiology, 2007, 102, 453-459.	2.5	103
88	Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Research in Cardiology, 2015, 110, 453.	2.5	103
89	SGLT2 Inhibitor, Canagliflozin, AttenuatesÂMyocardial Infarction in theÂDiabeticÂand Nondiabetic Heart. JACC Basic To Translational Science, 2019, 4, 15-26.	1.9	101
90	Stable High Level Expression of a Transfected Human HSP70 Gene Protects a Heart-Derived Muscle Cell Line Against Thermal Stress. Journal of Molecular and Cellular Cardiology, 1994, 26, 695-699.	0.9	100

#	Article	IF	Citations
91	Reperfusion Injury Revisited Is There a Role for Growth Factor Signaling in Limiting Lethal Reperfusion Injury?. Trends in Cardiovascular Medicine, 1999, 9, 245-249.	2.3	99
92	Loss of PINK1 Increases the Heart's Vulnerability to Ischemia-Reperfusion Injury. PLoS ONE, 2013, 8, e62400.	1.1	99
93	Cardioprotective Effects of Transforming Growth Factor-Î²1 During Early Reoxygenation or Reperfusion Are Mediated by p42/p44 MAPK. Journal of Cardiovascular Pharmacology, 2001, 38, 930-939.	0.8	98
94	The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Research in Cardiology, 2000, 95, 472-478.	2.5	96
95	Myocardial Protection Afforded by Nicorandil and Ischaemic Preconditioning in a Rabbit Infarct Model In Vivo. Journal of Cardiovascular Pharmacology, 1998, 31, 74-79.	0.8	95
96	Insulin therapy as an adjunct toreperfusion after acute coronary ischemia. Journal of the American College of Cardiology, 2003, 41, 1404-1407.	1.2	94
97	Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clinical Research in Cardiology, 2012, 101, 339-348.	1.5	91
98	Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. Journal of Molecular and Cellular Cardiology, 2003, 35, 1063-1071.	0.9	88
99	Cardioprotective growth factors. Cardiovascular Research, 2009, 83, 179-194.	1.8	87
100	Chronic Metformin Associated Cardioprotection Against Infarction: Not Just a Glucose Lowering Phenomenon. Cardiovascular Drugs and Therapy, 2013, 27, 5-16.	1.3	86
101	Prolonging the Delayed Phase of Myocardial Protection: Repetitive Adenosine A1Receptor Activation Maintains Rabbit Myocardium in a Preconditioned State 11Dr. Dana is supported by a Junior Research Fellowship, and Dr. Baxter by an Intermediate Fellowship, from the British Heart Foundation, London. Continuing support (Drs. Dana and Baxter) is provided by the Hatter Foundation, London.. Journal of the American College of Cardiology, 1998, 31, 1142-1149.	1.2	85
102	Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Research in Cardiology, 2016, 111, 50.	2.5	84
103	The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opinion on Therapeutic Targets, 2020, 24, 723-730.	1.5	84
104	Stromal derived factor 1Î±: A chemokine that delivers a two-pronged defence of the myocardium. , 2014, 143, 305-315.		82
105	Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of nonâ€diabetic exosomes <i>in vitro</i>. Journal of Cellular and Molecular Medicine, 2018, 22, 141-151.	1.6	82
106	Ischaemic preconditioning of the vasculature: an overlooked phenomenon for protecting the heart?. Trends in Pharmacological Sciences, 2000, 21, 225-230.	4.0	81
107	Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovascular Diabetology, 2013, 12, 154.	2.7	81
108	Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning. Scientific Reports, 2018, 8, 15885.	1.6	80

#	Article	IF	Citations
109	Genistein, a Tyrosine Kinase Inhibitor, Blocks the â€œSecond Window of Protectionâ€•48 h after Ischemic Preconditioning in the Rabbit. Journal of Molecular and Cellular Cardiology, 1997, 29, 1885-1893.	0.9	78
110	Exosomes and cardioprotection â€“ A critical analysis. Molecular Aspects of Medicine, 2018, 60, 104-114.	2.7	78
111	Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis. Journal of the American College of Cardiology, 2015, 65, 2764-2765.	1.2	77
112	Myocardial postconditioning: reperfusion injury revisited. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H2-H7.	1.5	76
113	Adipocytokines, cardiovascular pathophysiology and myocardial protection. , 2011, 129, 206-219.		76
114	Ischemic preconditioning targets the reperfusion phase. Basic Research in Cardiology, 2007, 102, 445-452.	2.5	74
115	Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovascular Research, 2013, 99, 694-704.	1.8	74
116	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Research in Cardiology, 2021, 116, 52.	2.5	73
117	Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 83-96.	1.0	71
118	Remote ischaemic conditioning reduces infarct size in animal<i>in vivo</i>models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovascular Research, 2017, 113, cvw219.	1.8	71
119	Atorvastatin and Myocardial Reperfusion Injury. Journal of Cardiovascular Pharmacology, 2005, 45, 247-252.	0.8	70
120	Preconditioning the diabetic human myocardium. Journal of Cellular and Molecular Medicine, 2010, 14, 1740-1746.	1.6	70
121	Necroptosis, necrostatins and tissue injury. Journal of Cellular and Molecular Medicine, 2011, 15, 1797-1806.	1.6	69
122	Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism. Pharmacological Research, 2016, 103, 318-327.	3.1	69
123	Adenosine A ₁ Receptor Activation Induces Delayed Preconditioning in Rats Mediated by Manganese Superoxide Dismutase. Circulation, 2000, 101, 2841-2848.	1.6	68
124	Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor. Journal of Cardiovascular Pharmacology, 2009, 53, 373-378.	0.8	68
125	Transitory Activation of AMPK at Reperfusion Protects the Ischaemic-Reperfused Rat Myocardium Against Infarction. Cardiovascular Drugs and Therapy, 2010, 24, 25-32.	1.3	68
126	Exosomes and Cardiovascular Protection. Cardiovascular Drugs and Therapy, 2017, 31, 77-86.	1.3	68

#	Article	IF	Citations
127	Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opinion on Pharmacotherapy, 2012, 13, 1153-1175.	0.9	67
128	Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart, 2011, 97, 1560-1565.	1.2	66
129	Pioglitazone Mimics Preconditioning in the Isolated Perfused Rat Heart. Journal of Cardiovascular Pharmacology, 2005, 46, 817-822.	0.8	64
130	Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovascular Research, 2012, 93, 445-453.	1.8	64
131	Î²3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. Basic Research in Cardiology, 2014, 109, 422.	2.5	63
132	Small extracellular vesicles secreted from human amniotic fluid mesenchymal stromal cells possess cardioprotective and promigratory potential. Basic Research in Cardiology, 2020, 115, 26.	2.5	62
133	Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Research in Cardiology, 2008, 103, 560-568.	2.5	61
134	Erythropoietin: ready for prime-time cardioprotection. Trends in Pharmacological Sciences, 2008, 29, 258-267.	4.0	61
135	Postconditioning for protection of the infarcting heart. Lancet, The, 2006, 367, 456-458.	6.3	60
136	Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. Basic Research in Cardiology, 2018, 113, 25.	2.5	59
137	Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal, 2015, 36, 1846-8.	1.0	59
138	Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. Journal of Cellular and Molecular Medicine, 2011, 15, 2443-2451.	1.6	58
139	Contrastâ€induced acute kidney injury following <scp>PCI</scp>. European Journal of Clinical Investigation, 2013, 43, 483-490.	1.7	56
140	The role of PI3KÎ± isoform in cardioprotection. Basic Research in Cardiology, 2017, 112, 66.	2.5	56
141	Quantifying the Area at Risk in Reperfused ST-Segmentâ€“Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomographyâ€“Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2016, 9, e003900.	1.3	54
142	Conditioning the whole heartâ€"not just the cardiomyocyte. Journal of Molecular and Cellular Cardiology, 2012, 53, 24-32.	0.9	53
143	Characterization of the Langendorff Perfused Isolated Mouse Heart Model of Global Ischemiaâ€“Reperfusion Injury. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 286-295.	1.0	53
144	Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Research in Cardiology, 2020, 115, 73.	2.5	49

#	Article	IF	Citations
145	Phentolamine and Preconditioning During Coronary Angioplasty. Circulation, 1998, 98, 378-379.	1.6	48
146	Nitric oxide as a mediator of delayed pharmacological (A1 receptor triggered) preconditioning; is eNOS masquerading as iNOS?. Cardiovascular Research, 2002, 53, 405-413.	1.8	48
147	Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2AReceptor Agonist: Role of A2AReceptor and Erk1/2. Cardiovascular Drugs and Therapy, 2003, 17, 415-425.	1.3	48
148	The Diabetic Heart: Too Sweet for Its Own Good?. Cardiology Research and Practice, 2012, 2012, 1-15.	0.5	48
149	SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes and Endocrinology,the, 2018, 6, 435-437.	5.5	47
150	Cardioprotection. Circulation, 2016, 134, 574-575.	1.6	46
151	Temporal Changes in Myocardial Salvage Kinases During Reperfusion Following Ischemia: Studies Involving the Cardioprotective Adipocytokine Apelin. Cardiovascular Drugs and Therapy, 2007, 21, 409-414.	1.3	45
152	Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore. Cardiovascular Research, 2015, 108, 357-366.	1.8	44
153	The divergent roles of protein kinase C epsilon and delta in simulated ischaemiaâ€"reperfusion injury in human myocardium. Journal of Molecular and Cellular Cardiology, 2009, 46, 758-764.	0.9	43
154	The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway. Cardiovascular Drugs and Therapy, 2018, 32, 165-168.	1.3	43
155	Remote Ischemic Conditioning: A Clinical Trialâ€™s Update. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 304-312.	1.0	42
156	From Protecting the Heart to Improving Athletic Performance â€" the Benefits of Local and Remote Ischaemic Preconditioning. Cardiovascular Drugs and Therapy, 2015, 29, 573-588.	1.3	41
157	From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on â€œNew frontiers in cardiovascular researchâ€. Basic Research in Cardiology, 2016, 111, 69.	2.5	41
158	Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response. Basic Research in Cardiology, 2021, 116, 12.	2.5	41
159	There is More to Life than Revascularization: Therapeutic Targeting of Myocardial Ischemia/Reperfusion Injury. Cardiovascular Therapeutics, 2011, 29, e67-e79.	1.1	40
160	Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. Journal of the American College of Cardiology, 2001, 37, 1996-2001.	1.2	39
161	â€˜Conditioningâ€™ the heart during surgery. European Journal of Cardio-thoracic Surgery, 2009, 35, 977-987.	0.6	39
162	Characterization of acute ischemia-related physiological responses associated with remote ischemic preconditioning: a randomized controlled, crossover human study. Physiological Reports, 2014, 2, e12200.	0.7	38

#	Article	IF	Citations
163	Role of Caspase 1 in Ischemia/Reperfusion Injury of the Myocardium. Journal of Cardiovascular Pharmacology, 2019, 74, 194-200.	0.8	38
164	The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Research in Cardiology, 2009, 104, 781-792.	2.5	36
165	Therapeutic strategies utilizing SDF-1Î± in ischaemic cardiomyopathy. Cardiovascular Research, 2018, 114, 358-367.	1.8	36
166	Characterisation and validation of a new murine model of global ischaemia-reperfusion injury. , 1998, 186, 61-68.		33
167	GLP-1 Therapy. Circulation: Heart Failure, 2008, 1, 147-149.	1.6	33
168	A critical review on the translational journey of cardioprotective therapies!. International Journal of Cardiology, 2016, 220, 176-184.	0.8	33
169	Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analoguesâ€"Liraglutide and Semaglutide. Cardiovascular Drugs and Therapy, 2019, 33, 661-667.	1.3	33
170	The Akt1 isoform is an essential mediator of ischaemic preconditioning. Journal of Cellular and Molecular Medicine, 2012, 16, 1739-1749.	1.6	32
171	Glimepiride Treatment Facilitates Ischemic Preconditioning in the Diabetic Heart. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 263-269.	1.0	32
172	Increased production of functional small extracellular vesicles in senescent endothelial cells. Journal of Cellular and Molecular Medicine, 2020, 24, 4871-4876.	1.6	32
173	Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic Research in Cardiology, 2021, 116, 32.	2.5	32
174	A future for remote ischaemic conditioning in high-risk patients. Basic Research in Cardiology, 2020, 115, 35.	2.5	31
175	Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovascular Research, 2022, 118, 282-294.	1.8	31
176	Urocortin: a protective peptide that targets both the myocardium and vasculature. Pharmacological Reports, 2009, 61, 172-182.	1.5	30
177	The pleiotropic effects of metformin: time for prospective studies. Cardiovascular Diabetology, 2015, 14, 109.	2.7	30
178	Role of PI3K in myocardial ischaemic preconditioning: mapping proâ€survival cascades at the trigger phase and at reperfusion. Journal of Cellular and Molecular Medicine, 2018, 22, 926-935.	1.6	30
179	Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERICâ€ONC Studyâ€"A Singleâ€Center, Blinded, Randomized Controlled Trial. Clinical Cardiology, 2016, 39, 72-82.	0.7	29
180	Bradykinin elicits â€œsecond windowâ€• myocardial protection in rat heart through an NO-dependent mechanism. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1458-H1464.	1.5	28

#	Article	IF	Citations
181	A Potential Role for PTEN in the Diabetic Heart. Cardiovascular Drugs and Therapy, 2006, 20, 319-321.	1.3	25
182	Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. Basic Research in Cardiology, 2013, 108, 331.	2.5	23
183	Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial. Clinical Research in Cardiology, 2014, 103, 203-209.	1.5	23
184	Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology, 2019, 18, 168.	2.7	23
185	Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Research in Cardiology, 2011, 106, 1387-1395.	2.5	21
186	Preconditioning and Arrhythmias. Circulation, 2002, 106, 2999-3001.	1.6	19
187	The importance of clinically relevant background therapy in cardioprotective studies. Basic Research in Cardiology, 2020, 115, 69.	2.5	19
188	The Role of Extracellular DNA and Histones in Ischaemia-Reperfusion Injury of the Myocardium. Cardiovascular Drugs and Therapy, 2020, 34, 123-131.	1.3	19
189	Extracellular histones are a target in myocardial ischaemiaâ€“reperfusion injury. Cardiovascular Research, 2022, 118, 1115-1125.	1.8	19
190	The Cardioprotective Actions of Leptin Are Lost in the Zucker Obese (fa/fa) Rat. Journal of Cardiovascular Pharmacology, 2009, 53, 311-317.	0.8	18
191	A retrospective analysis of myocardial preservation techniques during coronary artery bypass graft surgery: are we protecting the heart?. Journal of Cardiothoracic Surgery, 2014, 9, 184.	0.4	18
192	Combination Therapy to Target Reperfusion Injury After ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2017, 136, 904-906.	1.6	18
193	The GTN patch: a simple and effective new approach to cardioprotection?. Basic Research in Cardiology, 2018, 113, 20.	2.5	18
194	Stromal cell-derived factor-1Î± signals via the endothelium to protect the heart against ischaemia-reperfusion injury. Journal of Molecular and Cellular Cardiology, 2019, 128, 187-197.	0.9	17
195	Exogenous Administration of Recombinant MIF at Physiological Concentrations Failed to Attenuate Infarct Size in a Langendorff Perfused Isolated Mouse Heart Model. Cardiovascular Drugs and Therapy, 2016, 30, 445-453.	1.3	16
196	Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality. Heart, 2018, 104, 313-317.	1.2	16
197	Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway. Cardiovascular Drugs and Therapy, 2018, 32, 245-253.	1.3	16
198	â€œConditional Conditioningâ€•in cardiac bypass surgery. Basic Research in Cardiology, 2012, 107, 258.	2.5	15

#	Article	IF	Citations
199	Neuroprotection by remote ischemic conditioning in the setting of acute ischemic stroke: a preclinical two-centre study. Scientific Reports, 2020, 10, 16874.	1.6	15
200	Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130. Journal of Cellular and Molecular Medicine, 2021, 25, 4455-4465.	1.6	14
201	The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the <scp>ERICâ€GTN</scp> Study. Clinical Cardiology, 2015, 38, 641-646.	0.7	13
202	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. Cardiovascular Research, 2021, 117, 623-634.	1.8	13
203	Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Research in Cardiology, 2021, 116, 59.	2.5	13
204	Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute. Cardiovascular Drugs and Therapy, 2018, 32, 127-133.	1.3	12
205	Failure of the Adipocytokine, Resistin, to Protect the Heart From Ischemia-Reperfusion Injury. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 63-71.	1.0	11
206	Taking lizard saliva to heart. European Heart Journal, 2012, 33, 1426-1430.	1.0	11
207	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. Cardiovascular Research, 2017, 113, 1418-1419.	1.8	11
208	Mitochondrial PINK1â€"A Novel Cardioprotective Kinase?. Cardiovascular Drugs and Therapy, 2008, 22, 507-508.	1.3	10
209	Myocardial protection: is primary PCI enough?. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 12-13.	3.3	9
210	A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?. International Journal of Cardiology, 2017, 228, 198-200.	0.8	9
211	Hypoxic preconditioning of ischaemic myocardium. Cardiovascular Research, 1992, 26, 556-557.	1.8	8
212	162â€...Polymersomes Functionalized with HSP70 â€" Novel, Synthetic Cardioprotective Nanovesicles. Heart, 2016, 102, A115.2-A115.	1.2	7
213	Do We Really Need Aspirin Loading for STEMI?. Cardiovascular Drugs and Therapy, 2022, 36, 1221-1238.	1.3	7
214	Adenosine-Induced Second Window of Protection is Mediated by Inhibition of Mitochondrial Permeability Transition Pore Opening at the Time of Reperfusion. Cardiovascular Drugs and Therapy, 2004, 18, 79-80.	1.3	6
215	Endothelial Insulin Resistance Protects the Heart Against Prolonged Ischemiaâ€"Reperfusion Injury But Does Not Prevent Insulin Transport Across the Endothelium in a Mouse Langendorff Model. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 586-591.	1.0	6
216	Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial. Efficacy and Mechanism Evaluation, 2016, 3, 1-58.	0.9	6

#	Article	IF	Citations
217	STAT5 fits the RISK profile for cardioprotection. Jak-stat, 2012, 1, 73-76.	2.2	5
218	Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial. Cardiovascular Drugs and Therapy, 2023, 37, 299-305.	1.3	5
219	Negative interaction between nitrates and remote ischemic preconditioning in patients undergoing cardiac surgery: the ERIC-GTN and ERICCA studies. Basic Research in Cardiology, 2022, 117, .	2.5	5
220	Postconditioning does not protect the diabetic heart. Journal of Molecular and Cellular Cardiology, 2006, 40, 958.	0.9	4
221	A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. PLoS ONE, 2017, 12, e0174447.	1.1	4
222	Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?. Neural Regeneration Research, 2020, 15, 1852.	1.6	4
223	The metabolic syndrome raises the threshold for cardioprotection. Journal of Molecular and Cellular Cardiology, 2007, 42, S185.	0.9	3
224	Urocortin: A Few Inflammatory Remarks. Endocrinology, 2009, 150, 5205-5207.	1.4	3
225	Cardioprotection â€“ is no the answer? A renewed look at nitric oxide signalling in cardiomyocytes. Cardiovascular Research, 2018, 114, 773-775.	1.8	3
226	RIC in COVID-19â€"a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19. Cardiovascular Drugs and Therapy, 2022, 36, 925-930.	1.3	3
227	Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart. Journal of Molecular and Cellular Cardiology, 2007, 42, S177.	0.9	2
228	Remote ischaemic conditioningâ€"approaching prime time?. Nature Reviews Cardiology, 2013, 10, 619-621.	6.1	2
229	Ventilation strategy has a major influence on remote ischaemic preconditioning in mice. Journal of Cellular and Molecular Medicine, 2017, 21, 2426-2431.	1.6	2
230	Xenon. Journal of the American College of Cardiology, 2017, 70, 2661-2662.	1.2	2
231	Protection From Cardiac Ischemia-Reperfusion Injury by Epigenetic Regulation of NADPH Oxidase. Circulation, 2018, 138, 2837-2840.	1.6	2
232	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , .	1.4	2
233	Inhibiting mitochondrial permeability transition pore opening: A new paradigm in myocardial preconditioning?. Journal of Molecular and Cellular Cardiology, 2002, 34, A28.	0.9	1
234	p38 MAPK appears to be involved in the cytoprotective effect of insulin therapy administrated at reperfusion. Journal of Molecular and Cellular Cardiology, 2006, 40, 973.	0.9	1

#	Article	IF	Citations
235	Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Journal of Molecular and Cellular Cardiology, 2007, 42, S171.	0.9	1
236	Apelin, the potentially therapeutic adipocytokine, protects against myocardial ischemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2007, 42, S208.	0.9	1
237	Metformin cardioprotects the diabetic heart by inhibiting mPTP opening via the risk pathway. Journal of Molecular and Cellular Cardiology, 2007, 42, S217.	0.9	1
238	The cardioprotective effect of atorvastatinâ€"Is there a role for the adenosine receptor?. Journal of Molecular and Cellular Cardiology, 2008, 44, 778-779.	0.9	1
239	224â€...Stromal Derived Factor 1 Alpha is a Mediator of Conditioning in Human and Rat Myocardium. Heart, 2014, 100, A121.2-A122.	1.2	1
240	Evaluating early and delayed cardioprotection by plasma exosomes in simulated ischaemiaâ€"reperfusion injury. Bioscience Horizons, 2015, 8, .	0.6	1
241	Promising strategies to minimize reperfusion injury in STEMI. Minerva Cardioangiologica, 2016, 64, 284-94.	1.2	1
242	Editorial Cardiovascular & Renal: Ischaemic preconditioning: rational basis for drug design. Expert Opinion on Investigational Drugs, 1996, 5, 1435-1442.	1.9	0
243	Atorvastatin limits repertusion injury via activation of PI3K and eNOS. Journal of Molecular and Cellular Cardiology, 2002, 34, A8.	0.9	0
244	Apelin a vasoactive adipocytokine, exhibits direct cardioprotective effects. Journal of Molecular and Cellular Cardiology, 2006, 40, 956.	0.9	0
245	Metformin protects against myocardial reperfusion injury via PI3-kinase-dependent inhibition of mitochondrial permeability transition. Journal of Molecular and Cellular Cardiology, 2006, 40, 961.	0.9	0
246	Leptin, the obesity-related adipocytokine, protects the myocardium against ischaemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2006, 40, 963.	0.9	0
247	Erythropoietin protects against ischaemiaâ€"reperfusion injury in the human muscle via PI3-kinase activation. Journal of Molecular and Cellular Cardiology, 2006, 40, 966.	0.9	0
248	Transient upper arm ischemia reduces myocardial injury in patients undergoing cardiac bypass surgery. Journal of Molecular and Cellular Cardiology, 2007, 42, S181.	0.9	0
249	Erythropoietin reduces caspase 3 activation in the human atrial muscle undegoing hypoxia/reoxygenation injury. Journal of Molecular and Cellular Cardiology, 2007, 42, S191.	0.9	0
250	Cardioprotective actions of necrostatin. Journal of Molecular and Cellular Cardiology, 2007, 42, S193.	0.9	0
251	AMPK activation at reperfusion: A novel cardioprotective target?. Journal of Molecular and Cellular Cardiology, 2007, 42, S207.	0.9	0
252	Pten haploinsufficiency is not able to protect the myocardium against ischaemia reperfusion injury. Journal of Molecular and Cellular Cardiology, 2007, 42, S207-S208.	0.9	0

#	Article	IF	Citations
253	Leptin-induced cardioprotection is dependent on the presence of functional OB-Rb receptors. Journal of Molecular and Cellular Cardiology, 2007, 42, S208.	0.9	0
254	Cardioprotective actions of the novel adipocytokine visfatin. Journal of Molecular and Cellular Cardiology, 2007, 42, S216-S217.	0.9	0
255	Over-expression of the cardioprotective kinase Akt modulates mitochondrial morphology. Journal of Molecular and Cellular Cardiology, 2008, 44, 726.	0.9	0
256	The adipocytokine, resistin, is not cardioprotective despite activating components of the risk pathway. Journal of Molecular and Cellular Cardiology, 2008, 44, 728.	0.9	0
257	Rimonabant protects against myocardial ischemiaâ€"reperfusion injury in vivo. Journal of Molecular and Cellular Cardiology, 2008, 44, 728-729.	0.9	0
258	Can high-dose atorvastatin provide cardioprotection during coronary artery bypass surgery?. Journal of Molecular and Cellular Cardiology, 2008, 44, 729.	0.9	0
259	The human diabetic myocardium has a higher threshold for protection against simulated ischaemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2008, 44, 731-732.	0.9	0
260	Protein kinase C delta and epsilon isoforms have divergent roles in simulated ischaemiaâ€"reperfusion injury in human atrial muscle. Journal of Molecular and Cellular Cardiology, 2008, 44, 732.	0.9	0
261	Metformin protects against myocardial infarction independent of its glucose lowering effects. Journal of Molecular and Cellular Cardiology, 2008, 44, 748.	0.9	0
262	Cardioprotection from ischaemiaâ€"reperfusion injury: Dissecting the PI3K/AKT pathway with chemical inhibition of PTEN. Journal of Molecular and Cellular Cardiology, 2008, 44, 755-756.	0.9	0
263	Silencing PTEN, a negative regulator of the PI3K/AKT pathway, is not sufficient to confer protection against simulated ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology, 2008, 44, 756.	0.9	0
264	Remote ischaemic preconditioning confers cardioprotection over and above cardioplegia during cardiac surgery. Journal of Molecular and Cellular Cardiology, 2008, 44, 772-773.	0.9	0
265	Using multiphoton microscopy to examine the response of the heart to ischaemia and reperfusion injury. Journal of Molecular and Cellular Cardiology, 2008, 44, 778.	0.9	0
266	Leptin-stimulated inhibition of mitochondrial permeability transition is dependent on presence of functional OB-RB leptin receptor. Journal of Molecular and Cellular Cardiology, 2008, 44, 782.	0.9	0
267	Rho-kinase mediates reoxygenation-induced cardiomyocyte death and promotes mitochondrial transition pore opening. Journal of Molecular and Cellular Cardiology, 2008, 44, 791-792.	0.9	0
268	Corrigendum to â€œâ€˜Conditioningâ€™ the heart during surgeryâ€•[Eur. J. Cardiothorac. Surg. 35 (6) (2009) 977â€"987]. European Journal of Cardio-thoracic Surgery, 2009, 36, 608-608.	0.6	0
269	Reply to Landoni et al.. European Journal of Cardio-thoracic Surgery, 2010, 37, 983-983.	0.6	0
270	THE DIFFERENTIAL EFFECTS OF SIRTUIN-3 IN CARDIO-PROTECTION. Heart, 2014, 100, A9.2-A9.	1.2	0

#	Article	IF	Citations
271	Pharmacological cardioprotection in diabetes. Diabetes Management, 2015, 5, 89-101.	0.5	0
272	Remote Ischaemic Conditioning in Carotid Artery Stenting. Circulation, 2017, 135, 1336-1338.	1.6	0
273	Apoptosis, A Double-Edge Sword!. JACC Basic To Translational Science, 2017, 2, 498.	1.9	0
274	193â€…The role of the pi3k-alpha isoform in cardioprotection. Heart, 2017, 103, A131.2-A131.	1.2	0
275	BS10â€…Canagliflozin, an SGLT2 inhibitor attenuates ischaemia/reperfusion injury in the non-diabetic heart. , 2019, , .		0
276	Preventing the Cancer Patient ofÂTodayÂFromÂBecoming the HeartÂFailureÂPatientÂof Tomorrow. JACC: CardioOncology, 2019, 1, 235-237.	1.7	0
277	Abstract P752: Neuroprotection by Remote Ischemic Conditioning in the Setting of Acute Ischemic Stroke: A Preclinical Two-Centre International Study. Stroke, 2021, 52, .	1.0	0
278	Novel Treatment Strategies. , 2012, , 261-291.		0
279	Preconditioning in the Heart. , 2013, , 51-101.		0
280	Opioids in Acute Coronary Syndromes: Friend or Foe?. Cardiovascular Drugs and Therapy, 0, , .	1.3	0